Literature DB >> 19158978

Easing the burden of bipolar disorder: from urgent situations to remission.

.   

Abstract

Entities:  

Year:  2008        PMID： 19158978      PMCID： PMC2629059          DOI： 10.4088/pcc.v10n0507

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN： 1523-5998


× No keyword cloud information.
  79 in total

1.  The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.

Authors:  G Chen; L D Huang; Y M Jiang; H K Manji
Journal:  J Neurochem       Date:  1999-03       Impact factor: 5.372

2.  Lost time, absence costs, and reduced productivity output for employees with bipolar disorder.

Authors:  Nathan L Kleinman; Richard A Brook; Krithika Rajagopalan; Harold H Gardner; Truman J Brizee; James E Smeeding
Journal:  J Occup Environ Med       Date:  2005-11       Impact factor: 2.162

Review 3.  Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.

Authors:  Roy H Perlis; Jeffrey A Welge; Lana A Vornik; Robert M A Hirschfeld; Paul E Keck
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 4.  Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations.

Authors:  Lakshmi N Yatham; Vivek Kusumakar; Joseph R Calabrese; Rajeev Rao; Gayle Scarrow; Garth Kroeker
Journal:  J Clin Psychiatry       Date:  2002-04       Impact factor: 4.384

5.  Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study.

Authors:  Lewis L Judd; Hagop S Akiskal; Pamela J Schettler; Jean Endicott; Andrew C Leon; David A Solomon; William Coryell; Jack D Maser; Martin B Keller
Journal:  Arch Gen Psychiatry       Date:  2005-12

6.  The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death.

Authors:  R M Sapolsky
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

7.  Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.

Authors:  Andrew A Nierenberg; Michael J Ostacher; Joseph R Calabrese; Terence A Ketter; Lauren B Marangell; David J Miklowitz; Sachiko Miyahara; Mark S Bauer; Michael E Thase; Stephen R Wisniewski; Gary S Sachs
Journal:  Am J Psychiatry       Date:  2006-02       Impact factor: 18.112

8.  Suicide risk in bipolar disorder during treatment with lithium and divalproex.

Authors:  Frederick K Goodwin; Bruce Fireman; Gregory E Simon; Enid M Hunkeler; Janelle Lee; Dennis Revicki
Journal:  JAMA       Date:  2003-09-17       Impact factor: 56.272

9.  Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.

Authors:  Gary S Sachs; Fred Grossman; S Nassir Ghaemi; Akiko Okamoto; Charles L Bowden
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

10.  Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes.

Authors:  Mauricio Tohen; Charles L Bowden; Anatoly B Smulevich; Richard Bergstrom; Tonya Quinlan; Olawale Osuntokun; Wei V Wang; Heather S Oliff; Ferenc Martenyi; Ludmila A Kryzhanovskaya; Waldemar Greil
Journal:  Br J Psychiatry       Date:  2008-02       Impact factor: 9.319
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.